Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

芳香化酶抑制剂治疗绝经后妇女晚期乳腺癌

Información

DOI:
https://doi.org/10.1002/14651858.CD003370.pub3Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 07 octubre 2009see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Cáncer de mama

Copyright:
  1. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Lorna Gibson

    London School of Hygiene and Tropical Medicine, London, UK

  • David Lawrence

    Cancer Research UK and UCL Cancer Trials Centre, London, UK

  • Claire Dawson

    Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, UK

  • Judith Bliss

    Correspondencia a: Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, UK

    [email protected]

Contributions of authors

Judith Bliss wrote the original protocol, initiated the review with Lorna Gibson and reviewed the review.

Lorna Gibson worked with the Cochrane Breast Group to identify the initial list of references; she then worked through the list to identify eligible trials. Lorna carried out the first independent data extraction from the eligible trials and was a main contributor to the review and analysis, and the update.

Claire Dawson carried out a second independent extraction of data from the eligible trials and contributed to the original review.

David Lawrence carried out an independent check of the data extraction for accuracy and consistency and was a main contributor to the original review analysis, and the update.

Sources of support

Internal sources

  • Cancer Research UK, UK

External sources

  • No sources of support supplied

Declarations of interest

One of the authors (JMB) is a member of the management group and grant holder for the Intergroup Exemestane Study. This is funded by Pfizer, the producers of the aromatase inhibitor exemestane.

Acknowledgements

The authors were funded by Cancer Research UK. Lorna Gibson would like to thank Julian Peto and Isabel dos Santos Silva for their support. The authors would like to thank the Cochrane Breast Cancer Group for their support and are indebted to Olivia Fletcher for critical reading of the manuscript.

Version history

Published

Title

Stage

Authors

Version

2009 Oct 07

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

Review

Lorna Gibson, David Lawrence, Claire Dawson, Judith Bliss

https://doi.org/10.1002/14651858.CD003370.pub3

2009 Jul 08

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

Review

Lorna Gibson, Claire Dawson, David Lawrence, Judith Bliss

https://doi.org/10.1002/14651858.CD003370.pub2

2001 Oct 23

Aromatase Inhibitors for treatment of metastatic breast cancer

Protocol

Judith Bliss, Lorna Gibson

https://doi.org/10.1002/14651858.CD003370

Differences between protocol and review

Many of the data required to carry out analyses of prospectively identified subgroups, as set out in the review protocol, were not available. We could not, therefore, identify specific subgroups of women who may benefit from AI use.

Notes

This updated review includes the following additional seven trials to the 30 in the original publication: Chia 2008; Gale 1994; Garcia‐Giralt 1992; Goss 2007; Lundgren 1989; Samonis 1994. There were also two papers by Mourisden and colleagues (Mourisden 2004; Mourisden 2007) which contributed follow‐up information.

The update demonstrated a survival benefit of 10% with the use of AIs for the treatment of advanced (metastatic) breast cancer, compared to 11% in the original review.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.